Gautam Maddineni

Gautam Maddineni

Auto-generated profile, based on publicly available information

Gautam Maddineni

Florida State University, Tallahassee, FL

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
EAEhsan Amini-Salehi
Ehsan Amini-Salehi
SNSandeep Samethadka Nayak
Sandeep Samethadka Nayak
GMGautam Maddineni
Gautam Maddineni
AMAbinash Mahapatro
Abinash Mahapatro
MKMohammad-Hossein Keivanlou
Mohammad-Hossein Keivanlou
SHSoheil Hassanipour
Soheil Hassanipour
Background and aim: Modulating the gut microbiota population by administration of probiotics, prebiotics, and synbiotics has shown to have a variety of health benefits in different populations, particularly those with metabolic disorders. Although the promising effects of these compounds have been observed in the management of patients with non-alcoholic fatty liver disease (NAFLD), the exact effects and the mechanisms of action are yet to be understood. In the present study, we aimed to evaluate how gut microbiota modulation affects anthropometric indices of NAFLD patients to achieve a comprehensive summary of current evidence-based knowledge. Methods: Two researchers independently searched international databases, including PubMed, Scopus, and Web of Science, from inception to June 2023. Meta-analysis studies that evaluated the effects of probiotics, prebiotics, and synbiotics on patients with NAFLD were entered into our umbrella review. The data regarding anthropometric indices, including body mass index, weight, waist circumference (WC), and waist-to-hip ratio (WHR), were extracted by the investigators. The authors used random effect model for conducting the meta-analysis. Subgroup analysis and sensitivity analysis were also performed. Results: A total number of 13 studies were finally included in our study. Based on the final results, BMI was significantly decreased in NAFLD patients by modulation of gut microbiota [effect size (ES): −0.18, 05% CI: −0.25, −0.11, P<0.001]; however, no significant alteration was observed in weight and WC (ES: −1.72, 05% CI: −3.48, 0.03, P=0.055, and ES: −0.24, 05% CI: −0.75, 0.26, P=0.353, respectively). The results of subgroup analysis showed probiotics had the most substantial effect on decreasing BMI (ES: −0.77, 95% CI: −1.16, −0.38, P<0.001) followed by prebiotics (ES: −0.51, 95% CI: −0.76, −0.27, P<0.001) and synbiotics (ES: -0.12, 95% CI: −0.20, −0.04, P=0.001). Conclusion: In conclusion, the present umbrella meta-analysis showed that although modulation of gut microbiota by administration of probiotics, prebiotics, and synbiotics had promising effects on BMI, no significant change was observed in the WC and weight of the patients. No sufficient data were available for other anthropometric indices including waist-to-hip ratio and waist-to-height ratio and future meta-analyses should be done in this regard.

20 June 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
GMGautam Maddineni
Gautam Maddineni
SOSri J. Obulareddy
Sri J. Obulareddy
RPRuchir Damjibhai Paladiya
Ruchir Damjibhai Paladiya
RKRohan Reddy Korsapati
Rohan Reddy Korsapati
SJShika M. Jain
Shika M. Jain
DPDhruvan Patel
Dhruvan Patel
Background and aim: Currently, there are no authorized medications specifically for non-alcoholic fatty liver disease (NAFLD) treatment. Studies indicate that changes in gut microbiota can disturb intestinal balance and impair the immune system and metabolism, thereby elevating the risk of developing and exacerbating NAFLD. Despite some debate, the potential benefits of microbial therapies in managing NAFLD have been shown. Methods: A systematic search was undertaken to identify meta-analyses of randomized controlled trials that explored the effects of microbial therapy on the NAFLD population. The goal was to synthesize the existing evidence-based knowledge in this field. Results: The results revealed that probiotics played a significant role in various aspects, including a reduction in liver stiffness (MD: −0.38, 95% CI: [−0.49, −0.26]), hepatic steatosis (OR: 4.87, 95% CI: [1.85, 12.79]), decrease in body mass index (MD: −1.46, 95% CI: [−2.43, −0.48]), diminished waist circumference (MD: −1.81, 95% CI: [−3.18, −0.43]), lowered alanine aminotransferase levels (MD: −13.40, 95% CI: [−17.02, −9.77]), decreased aspartate aminotransferase levels (MD: −13.54, 95% CI: [−17.85, −9.22]), lowered total cholesterol levels (MD: −15.38, 95% CI: [−26.49, −4.26]), decreased fasting plasma glucose levels (MD: −4.98, 95% CI: [−9.94, −0.01]), reduced fasting insulin (MD: −1.32, 95% CI: [−2.42, −0.21]), and a decline in homeostatic model assessment of insulin resistance (MD: −0.42, 95% CI: [−0.72, −0.11]) (P<0.05). Conclusion: Overall, the results demonstrated that gut microbiota interventions could ameliorate a wide range of indicators including glycemic profile, dyslipidemia, anthropometric indices, and liver injury, allowing them to be considered a promising treatment strategy.

7 March 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MAMaryam Sadat Aleali
Maryam Sadat Aleali
AMAbinash Mahapatro
Abinash Mahapatro
GMGautam Maddineni
Gautam Maddineni
RPRuchir Paladiya
Ruchir Paladiya
HJHerby Jeanty
Herby Jeanty
EAEhsan Amini-Salehi
Ehsan Amini-Salehi
Background: Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic risk factors. Recent research highlights the gut microbiome’s role in metabolic regulation, suggesting that modulation through probiotics, prebiotics, and synbiotics may provide a novel approach to managing MetS. This umbrella review aims to integrate insights from existing meta-analyses to explore how changes in gut microbiota influence key body measurement indicators in individuals with MetS. Methods: A systematic search of PubMed, Scopus, and Web of Science databases identified meta-analyses that assessed the impact of probiotics, prebiotics, or synbiotics on anthropometric indices in MetS patients. Results: The results indicated that microbial therapy leads to a significant reduction in body mass index (BMI) (SMD: −0.22; 95% CI: −0.35 to −0.09; P < 0.01) and waist circumference (WC) (SMD: −0.47; 95% CI: −0.80 to −0.15; P < 0.01). However, microbial therapy did not significantly affect body fat mass (SMD: −0.30; 95% CI: −0.64 to 0.02; P = 0.06), body fat percentage (SMD: −0.29; 95% CI: −0.62 to 0.03; P = 0.07), waist-to-hip ratio (SMD: −0.09; 95% CI: −0.46 to 0.28; P = 0.63), and weight (SMD: −0.06; 95% CI: −0.21 to 0.08; P = 0.37). Conclusions: Gut microbial modulation, mainly through probiotics and synbiotics, shows promise in reducing BMI and WC in MetS patients. However, its effects on other anthropometric indices remain uncertain, warranting further high-quality research to fully understand microbial interventions’ therapeutic potential.

8 May 2026 in Medicine
Verified
Journal Article
Open access
AMAbinash Mahapatro
Abinash Mahapatro
HJHerby Jeanty
Herby Jeanty
SJSaisree Reddy Adla Jala
Saisree Reddy Adla Jala
KSKavya Priya Somu
Kavya Priya Somu
GMGautam Madineni
Gautam Madineni
AGArezoo Ghazalgoo
Arezoo Ghazalgoo
Background: Metabolic-associated fatty liver disease (MAFLD) affects approximately 30% of the global population and is associated with obesity and metabolic syndrome. Anthropometric indices such as body mass index (BMI), waist circumference (WC), and weight are crucial markers for evaluating the progression of MAFLD. Curcumin, a bioactive compound with anti-inflammatory and antioxidant properties, has been investigated for its potential to improve metabolic outcomes. This umbrella review aimed to systematically evaluate the effects of curcumin supplementation on anthropometric indices in patients with MAFLD, considering epidemiological strength and power analysis. Methods: An umbrella review of meta-analyses from randomized controlled trials was conducted. PubMed, Scopus, and Web of Science were searched up to September 2024. Meta-analyses assessing curcumin’s effects on BMI, weight, and WC in MAFLD patients were included. Quality was assessed using the A Measurement Tool to Assess Systematic Reviews version (AMSTAR-2) tool, and heterogeneity was evaluated using the I 2 statistic. Statistical analyses were performed using R and Stata 18 software. Results: Curcumin supplementation had no significant effect on BMI (standardized mean difference [SMD]: −0.01; 95% confidence interval [CI]: −0.24 to 0.21, P = .91) with low power (1-β = 0.03) and a low epidemiological grade according to GRADE criteria. Similarly, curcumin showed no significant effect on WC (SMD: −0.27; 95% CI: −0.57 to 0.04, P = .08) with high power (1-β = 0.96) but low epidemiological strength. However, curcumin significantly reduced weight (SMD: −0.12; 95% CI: −0.19 to −0.04, P < .01) with moderate power (1-β = 0.56) and moderate epidemiological strength. No significant effect of dose or effect of supplementation duration was found. Conclusion: Curcumin supplementation may result in a statistically detectable but clinically modest reduction in body weight in patients with MAFLD, while showing limited or no efficacy on BMI and waist circumference. The epidemiological strength of the evidence varies across outcomes and is of low to moderate quality. Further well-designed, high-quality randomized controlled trials are needed to confirm the clinical relevance of curcumin’s effects on anthropometric indices.